Core Insights - Royalty Pharma plc has appointed Molly Sawaya as Executive Vice President, Head of Human Capital, effective July 24, 2024 [1][4] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [8] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, and biotechnology companies, to fund innovation [8] - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 17 development-stage product candidates [8] Leadership Appointment - Molly Sawaya brings nearly 15 years of HR experience from large global organizations, focusing on creating environments for employee growth and engagement [4][7] - Prior to joining Royalty Pharma, Sawaya was a Managing Director at Hudson Bay Capital, where she led the HR agenda [7] - The CEO of Royalty Pharma, Pablo Legorreta, expressed confidence in Sawaya's ability to enhance the company's culture and support its growth [4]

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay ...

Group 1 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [1] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [1] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, featuring notable therapies such as Vertex's Trikafta and GSK's Trelegy [1] Group 2 - The board of directors of Royalty Pharma has approved a dividend of $0.21 per Class A ordinary share for the third quarter of 2024 [2] - The dividend payment is scheduled for September 13, 2024, to shareholders of record as of August 16, 2024 [4]

The bullish case only gets stronger once investors take into account RPRX's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend. The 50-day simple moving average is a widely ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Royalty Pharma (RPRX) , which belongs to the Zacks Financial - Miscellaneous Services industry, could be a great candidate to consider. For the most recent quarter, Royalty Pharma was expected to post earnings of $0.96 per share, but it reported $0.98 per share instead, representing a surprise of 2.08%. For the previous quarter, the consensus estimate ...

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to global pharmaceutical companies [2] - The company has a portfolio that includes royalties on more than 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, and Roche's Evrysdi, as well as 17 development-stage product candidates [2] Upcoming Events - Royalty Pharma is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:00 p.m. ET, with the webcast accessible on their "Events" page [1]

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expec ...

Core Viewpoint - Royalty Pharma plc has announced a $1.5 billion offering of senior unsecured notes, which will be used for general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of three tranches: $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054 [1]. - The notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd, with the offering expected to close on June 10, 2024, subject to customary closing conditions [2]. Group 2: Underwriters and Managers - BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley, and TD Securities are acting as joint lead bookrunning managers for the offering [3]. - Additional co-managers include DNB Markets, SMBC Nikko, SOCIETE GENERALE, US Bancorp, and several others [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry [6]. - The company collaborates with various entities, including academic institutions and leading global pharmaceutical companies, and has a portfolio that includes royalties on over 35 commercial products [6].

Core Viewpoint - Royalty Pharma has acquired a $905 million interest in Agios Pharmaceuticals' royalty on vorasidenib, contingent on FDA approval, which is expected to be a transformative therapy for IDH-mutant glioma patients [1][2][3]. Group 1: Acquisition Details - Royalty Pharma will pay Agios $905 million in upfront cash upon FDA approval of vorasidenib in exchange for a 15% royalty on annual U.S. net sales up to $1 billion and a 12% royalty on sales exceeding $1 billion [3]. - Agios will retain a 3% royalty on annual U.S. net sales greater than $1 billion [3]. Group 2: Product Information - Vorasidenib is an oral, selective dual inhibitor of IDH1/2 enzymes, targeting IDH-mutant diffuse glioma, with an estimated annual incidence of 1,500 patients and a prevalence of approximately 10,000 in the U.S. [2]. - The pivotal Phase 3 INDIGO clinical trial demonstrated significant efficacy and safety, meeting its primary endpoint of progression-free survival [2][8]. - Vorasidenib has received Breakthrough Therapy Designation from the FDA, with a PDUFA date set for August 20, 2024 [2][8]. Group 3: Financial Projections - Royalty Pharma projects peak annual sales for vorasidenib to exceed $1 billion, potentially generating over $150 million in annual royalties [4][8]. - If approved, royalties from vorasidenib are expected to continue through 2038 [4]. Group 4: Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [7]. - The company collaborates with various innovators, including academic institutions and biotechnology companies, to fund late-stage clinical trials and acquire existing royalties [7].

Core Insights - Vorasidenib, if approved, would be the first targeted therapy for IDH-mutant glioma, a progressive and incurable brain tumor [1][2] - The pivotal Phase 3 clinical study of vorasidenib showed unprecedented efficacy and tolerability, meeting its primary endpoint of progression-free survival [2][4] - Royalty Pharma has acquired an interest in Agios Pharmaceuticals' royalty on vorasidenib for $905 million, contingent on FDA approval [1][3] Financial Projections - Royalty Pharma projects peak annual sales for vorasidenib to exceed $1 billion in the U.S., with potential royalties exceeding $150 million annually [1][4] - Under the agreement, Royalty Pharma will pay Agios $905 million upfront upon FDA approval, receiving a 15% royalty on U.S. net sales up to $1 billion and a 12% royalty on sales exceeding that amount [3] Market Context - Vorasidenib targets IDH-mutant diffuse gliomas, which have an incidence of approximately 1,500 patients per year and a prevalence of around 10,000 in the U.S. [2] - The drug has received Breakthrough Therapy Designation from the FDA and is under priority review, with a PDUFA date set for August 20, 2024 [2][4]